文献速递胸部肿瘤

小细胞肺癌的细胞可塑性揭示其内在免疫原性

Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity.
PubMed 文献 · Cancer Discov · 2021-03-11

小细胞肺癌(SCLC)突变负荷高但免疫检查点阻断(ICB)持久缓解罕见。研究发现部分SCLC上调MHC I并富集持久ICB获益,体外模型显示神经内分泌分化丧失后MHC I表观遗传恢复并伴随STING去抑制;小鼠非神经内分泌SCLC被排斥,EZH2抑制后STING激动增强T细胞识别与排斥。

要点

  • MHC I高表达是SCLC免疫应答的新生物标志物
  • 非神经内分泌SCLC亚群具有内在免疫原性
  • EZH2抑制后STING激动可增强SCLC免疫排斥

核心结论

  • SCLC中存在MHC I高表达的非神经内分泌亚群,具有内在免疫原性并与持久ICB获益相关。
  • EZH2抑制后STING激动可揭示该细胞状态并增强小鼠SCLC的免疫排斥。

研究设计与样本

  • 研究对SCLC的细胞可塑性进行 profiling,并结合体外模型与小鼠同基因模型验证。

主要发现

  • 部分SCLC独特上调MHC I,富集持久ICB获益。
  • 体外模型证实神经内分泌分化丧失后MHC I表观遗传恢复,与STING去抑制相关。
  • 短暂EZH2抑制扩增非神经内分泌细胞,显示内在固有免疫信号和基础恢复的抗原呈递。
  • 小鼠非神经内分泌SCLC肿瘤在同基因模型中被排斥,伴免疫优势效应CD8 T细胞克隆扩增。
  • EZH2抑制后STING激动增强小鼠SCLC的T细胞识别和排斥。

临床怎么用

  • MHC I高表达或非神经内分泌状态可能用于筛选ICB获益的SCLC患者。
  • EZH2抑制后STING激动是值得进一步临床研究的SCLC免疫治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Small cell lung carcinoma (SCLC) is highly mutated, yet durable response to immune checkpoint blockade (ICB) is rare. SCLC also exhibits cellular plasticity, which could influence its immunobiology. Here we discover that a distinct subset of SCLC uniquely upregulates MHC I, enriching for durable ICB benefit. In vitro modeling confirms epigenetic recovery of MHC I in SCLC following loss of neuroendocrine differentiation, which tracks with derepression of STING. Transient EZH2 inhibition expands these nonneuroendocrine cells, which display intrinsic innate immune signaling and basally restored antigen presentation. Consistent with these findings, murine nonneuroendocrine SCLC tumors are rejected in a syngeneic model, with clonal expansion of immunodominant effector CD8 T cells. Therapeutically, EZH2 inhibition followed by STING agonism enhances T-cell recognition and rejection of SCLC in mice. Together, these data identify MHC I as a novel biomarker of SCLC immune responsiveness and suggest novel immunotherapeutic approaches to co-opt SCLC's intrinsic immunogenicity. SIGNIFICANCE: SCLC is poorly immunogenic, displaying modest ICB responsiveness with rare durable activity. In profiling its plasticity, we uncover intrinsically immunogenic MHC Ihi subpopulations of nonneuroendocrine SCLC associated with durable ICB benefit. We also find that combined EZH2 inhibition and STING agonism uncovers this cell state, priming cells for immune rejection.This article is highlighted in the In This Issue feature, p. 1861.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Mahadevan NR, Knelson EH, Wolff JO, et al. Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity. Cancer Discov. 2021. PMID: 33707236. doi:10.1158/2159-8290.CD-20-0913

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。